AD with subcortical white matter lesions and vascular dementia

CSF markers for differential diagnosis

Alessandro Stefani, Sergio Bernardini, Marta Panella, Mariangela Pierantozzi, Marzia Nuccetelli, Giacomo Koch, Andrea Urbani, Angela Giordano, Alessandro Martorana, Antonio Orlacchio, Giorgio Federici, Giorgio Bernardi

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

We investigated whether the cerebrospinal fluid (CSF) biomarkers beta-amyloid 1-42 (Aβ1-42), total tau (t-tau) protein and tau protein phosphorylated at threonine 181 (p-tau181) could discriminate Alzheimer's disease (AD) from vascular dementia (VD) patients. CSF samples of Aβ1-42, t-tau, and p-tau181 were collected from probable AD (n = 35), probable AD with white matter changes (WMC) indicative of concomitant cerebrovascular disorder (CVD, n = 31), VD (n = 20), and an age-matched subgroup of patients with other neurological disorders (OND) without cognitive impairment (n = 24). AD patients showed very low Aβ1-42 levels (median = 393 pg/ml). Aβ1-42, but not t-tau, differentiated AD from VD patients. However, the markers did not discriminate AD vs. AD plus WMC. In particular, both subgroups showed similar CSF biomarkers but they were significantly different from VD. ROC analysis showed that Aβ1-42 could discriminate AD from VD (AUC = 0.85). The cutoff of 493 pg/ml gave sensitivity and specificity values of 77% and 80%, respectively. Similar results were obtained when Aβ1-42 was employed to discriminate AD with WMC from VD (95% specificity and 60% sensitivity, but with cutoff of 750 pg/ml). T-tau increased aspecifically in all cognitively impaired patients. P-tau181 performed better than t-tau in discriminating AD (with or without WMC) vs. VD. In conclusion, Aβ1-42 proved to be a valuable tool to discriminate AD vs. VD patients and possibly to improve diagnostic accuracy in clinical forms, improperly classified as "mixed dementia" based on radiological vascular lesions.

Original languageEnglish
Pages (from-to)83-88
Number of pages6
JournalJournal of the Neurological Sciences
Volume237
Issue number1-2
DOIs
Publication statusPublished - Oct 15 2005

Fingerprint

Vascular Dementia
Cerebrospinal Fluid
Alzheimer Disease
Differential Diagnosis
Amyloid
tau Proteins
White Matter
Biomarkers
Cerebrovascular Disorders
Sensitivity and Specificity
Threonine
Nervous System Diseases
ROC Curve
Area Under Curve
Blood Vessels
Dementia

Keywords

  • Biomarkers
  • Cerebro-vascular disorder
  • Dementia
  • Diagnosis
  • White Matter Changes

ASJC Scopus subject areas

  • Ageing
  • Clinical Neurology
  • Surgery
  • Developmental Neuroscience
  • Neurology
  • Neuroscience(all)

Cite this

AD with subcortical white matter lesions and vascular dementia : CSF markers for differential diagnosis. / Stefani, Alessandro; Bernardini, Sergio; Panella, Marta; Pierantozzi, Mariangela; Nuccetelli, Marzia; Koch, Giacomo; Urbani, Andrea; Giordano, Angela; Martorana, Alessandro; Orlacchio, Antonio; Federici, Giorgio; Bernardi, Giorgio.

In: Journal of the Neurological Sciences, Vol. 237, No. 1-2, 15.10.2005, p. 83-88.

Research output: Contribution to journalArticle

Stefani, A, Bernardini, S, Panella, M, Pierantozzi, M, Nuccetelli, M, Koch, G, Urbani, A, Giordano, A, Martorana, A, Orlacchio, A, Federici, G & Bernardi, G 2005, 'AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis', Journal of the Neurological Sciences, vol. 237, no. 1-2, pp. 83-88. https://doi.org/10.1016/j.jns.2005.05.016
Stefani, Alessandro ; Bernardini, Sergio ; Panella, Marta ; Pierantozzi, Mariangela ; Nuccetelli, Marzia ; Koch, Giacomo ; Urbani, Andrea ; Giordano, Angela ; Martorana, Alessandro ; Orlacchio, Antonio ; Federici, Giorgio ; Bernardi, Giorgio. / AD with subcortical white matter lesions and vascular dementia : CSF markers for differential diagnosis. In: Journal of the Neurological Sciences. 2005 ; Vol. 237, No. 1-2. pp. 83-88.
@article{2bb952c7eb174ec48d0a70c0a4662b74,
title = "AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis",
abstract = "We investigated whether the cerebrospinal fluid (CSF) biomarkers beta-amyloid 1-42 (Aβ1-42), total tau (t-tau) protein and tau protein phosphorylated at threonine 181 (p-tau181) could discriminate Alzheimer's disease (AD) from vascular dementia (VD) patients. CSF samples of Aβ1-42, t-tau, and p-tau181 were collected from probable AD (n = 35), probable AD with white matter changes (WMC) indicative of concomitant cerebrovascular disorder (CVD, n = 31), VD (n = 20), and an age-matched subgroup of patients with other neurological disorders (OND) without cognitive impairment (n = 24). AD patients showed very low Aβ1-42 levels (median = 393 pg/ml). Aβ1-42, but not t-tau, differentiated AD from VD patients. However, the markers did not discriminate AD vs. AD plus WMC. In particular, both subgroups showed similar CSF biomarkers but they were significantly different from VD. ROC analysis showed that Aβ1-42 could discriminate AD from VD (AUC = 0.85). The cutoff of 493 pg/ml gave sensitivity and specificity values of 77{\%} and 80{\%}, respectively. Similar results were obtained when Aβ1-42 was employed to discriminate AD with WMC from VD (95{\%} specificity and 60{\%} sensitivity, but with cutoff of 750 pg/ml). T-tau increased aspecifically in all cognitively impaired patients. P-tau181 performed better than t-tau in discriminating AD (with or without WMC) vs. VD. In conclusion, Aβ1-42 proved to be a valuable tool to discriminate AD vs. VD patients and possibly to improve diagnostic accuracy in clinical forms, improperly classified as {"}mixed dementia{"} based on radiological vascular lesions.",
keywords = "Biomarkers, Cerebro-vascular disorder, Dementia, Diagnosis, White Matter Changes",
author = "Alessandro Stefani and Sergio Bernardini and Marta Panella and Mariangela Pierantozzi and Marzia Nuccetelli and Giacomo Koch and Andrea Urbani and Angela Giordano and Alessandro Martorana and Antonio Orlacchio and Giorgio Federici and Giorgio Bernardi",
year = "2005",
month = "10",
day = "15",
doi = "10.1016/j.jns.2005.05.016",
language = "English",
volume = "237",
pages = "83--88",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - AD with subcortical white matter lesions and vascular dementia

T2 - CSF markers for differential diagnosis

AU - Stefani, Alessandro

AU - Bernardini, Sergio

AU - Panella, Marta

AU - Pierantozzi, Mariangela

AU - Nuccetelli, Marzia

AU - Koch, Giacomo

AU - Urbani, Andrea

AU - Giordano, Angela

AU - Martorana, Alessandro

AU - Orlacchio, Antonio

AU - Federici, Giorgio

AU - Bernardi, Giorgio

PY - 2005/10/15

Y1 - 2005/10/15

N2 - We investigated whether the cerebrospinal fluid (CSF) biomarkers beta-amyloid 1-42 (Aβ1-42), total tau (t-tau) protein and tau protein phosphorylated at threonine 181 (p-tau181) could discriminate Alzheimer's disease (AD) from vascular dementia (VD) patients. CSF samples of Aβ1-42, t-tau, and p-tau181 were collected from probable AD (n = 35), probable AD with white matter changes (WMC) indicative of concomitant cerebrovascular disorder (CVD, n = 31), VD (n = 20), and an age-matched subgroup of patients with other neurological disorders (OND) without cognitive impairment (n = 24). AD patients showed very low Aβ1-42 levels (median = 393 pg/ml). Aβ1-42, but not t-tau, differentiated AD from VD patients. However, the markers did not discriminate AD vs. AD plus WMC. In particular, both subgroups showed similar CSF biomarkers but they were significantly different from VD. ROC analysis showed that Aβ1-42 could discriminate AD from VD (AUC = 0.85). The cutoff of 493 pg/ml gave sensitivity and specificity values of 77% and 80%, respectively. Similar results were obtained when Aβ1-42 was employed to discriminate AD with WMC from VD (95% specificity and 60% sensitivity, but with cutoff of 750 pg/ml). T-tau increased aspecifically in all cognitively impaired patients. P-tau181 performed better than t-tau in discriminating AD (with or without WMC) vs. VD. In conclusion, Aβ1-42 proved to be a valuable tool to discriminate AD vs. VD patients and possibly to improve diagnostic accuracy in clinical forms, improperly classified as "mixed dementia" based on radiological vascular lesions.

AB - We investigated whether the cerebrospinal fluid (CSF) biomarkers beta-amyloid 1-42 (Aβ1-42), total tau (t-tau) protein and tau protein phosphorylated at threonine 181 (p-tau181) could discriminate Alzheimer's disease (AD) from vascular dementia (VD) patients. CSF samples of Aβ1-42, t-tau, and p-tau181 were collected from probable AD (n = 35), probable AD with white matter changes (WMC) indicative of concomitant cerebrovascular disorder (CVD, n = 31), VD (n = 20), and an age-matched subgroup of patients with other neurological disorders (OND) without cognitive impairment (n = 24). AD patients showed very low Aβ1-42 levels (median = 393 pg/ml). Aβ1-42, but not t-tau, differentiated AD from VD patients. However, the markers did not discriminate AD vs. AD plus WMC. In particular, both subgroups showed similar CSF biomarkers but they were significantly different from VD. ROC analysis showed that Aβ1-42 could discriminate AD from VD (AUC = 0.85). The cutoff of 493 pg/ml gave sensitivity and specificity values of 77% and 80%, respectively. Similar results were obtained when Aβ1-42 was employed to discriminate AD with WMC from VD (95% specificity and 60% sensitivity, but with cutoff of 750 pg/ml). T-tau increased aspecifically in all cognitively impaired patients. P-tau181 performed better than t-tau in discriminating AD (with or without WMC) vs. VD. In conclusion, Aβ1-42 proved to be a valuable tool to discriminate AD vs. VD patients and possibly to improve diagnostic accuracy in clinical forms, improperly classified as "mixed dementia" based on radiological vascular lesions.

KW - Biomarkers

KW - Cerebro-vascular disorder

KW - Dementia

KW - Diagnosis

KW - White Matter Changes

UR - http://www.scopus.com/inward/record.url?scp=25644448985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25644448985&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2005.05.016

DO - 10.1016/j.jns.2005.05.016

M3 - Article

VL - 237

SP - 83

EP - 88

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -